MDM2i in myeloid malignancies harbors the possibility of a clonal selection of TP53 mutated cells; 30% of patients treated with idasanutlin expanded p53 mutated clones after therapy for R/R AML [9]. Here, TP53 is linked to acute myeloid leukemia.